Cochlear Limited Results for the half year ended 31 December 2011 (H1 F12) Chris Roberts, CEO Neville Mitchell, CFO
Cochlear Overview Cochlear Limited (ASX:COH): global leader in implantable devices for the hearing impaired (eg cochlear implants, bone conduction implants..) ~ 2,500 employees Direct operations in 20+ countries, and products sold in 100+ countries A focus on a long term partnership with recipients and healthcare professionals, with a particular emphasis on technologic innovation
Strategy post 11 September 2011 1. 11 Sep 2011: recalled unimplanted CI500 series implants (a component of Nucleus cochlear implant system) 2. Replaced with CI24RE implant (without any compromise in hearing performance) 3. Focus on global execution, for example, communication, manufacturing ramp up, and the like 4. Key growth initiatives that drive the business longer term kept in place
Communication has been a major focus Communication around the recall has been critical Objective was to be open, transparent and fact based Different external regulators, across different countries can make coordination of communication complex Overall, feedback from the field on the communication has been positive
CI500 Series Recall Current Status 1. As at 31 st January 2012, the proportion of registered CI500 implants that had failed was 2.4% 2. Newly reported implant failures have reduced every month since October 3. Implant failure mode consistent: loss of hermeticity causing malfunction of specific electronic components (typically 1 of 4 diodes) such that device shuts down 4. Clinical symptoms consistent: intermittency followed by device shut down 5. Root cause: unexpected variations in a brazing process forms basis for return of CI500 series 6. Fully expensed in H1 F12 ($100.5 million cost after tax). Cash costs estimated as $20 to $30 million (over time)
Cochlear: Financial Results for H1 F12 H1 F12 $m H1 F11 $m % Change Cochlear Implant Sales 311.5 309.6 1% Bone Anchored Solutions (Baha) Sales 39.7 45.6 13% FX Contracts Gains 36.3 21.9 66% Total Revenue 387.5 377.1 3% EBIT * 108.7 121.1 10% Net Profit after Tax * 80.1 87.2 8% Product Recall Costs, net of tax 100.5 - Net (loss)/profit attributable to members (20.4) 87.2 123% * These items exclude product recall expenses of $138.8 million before tax
Cochlear: Sales in Constant Currency (CC) H1 F12 revenues up 3% to $387.5 million in reported currency H2 H1 F12 sales in constant currency (prior periods restated at H1 F12 rates) up 5% H1
Cochlear: Cochlear Implant (CI) Unit Sales H1 F12 CI unit sales 9% to 10,724 implants H2 H1 This 10,724 excludes 2,300+ units shipped post recall not recognised as revenue (replacing unimplanted CI500) Given limited implant supply (post recall), shipments were to scheduled surgeries Record number of recipients receiving an implant, ie clinic destocking
Manufacturing and Global Supply Chain Rapid response to recall by manufacturing by December weekly production of cochlear implants was significantly above pre recall levels Investments in agility and flexibility over the past 5 years were critical to implementing this rapid response Supply of cochlear implants was limited, still only shipping to surgeries in December, no surgeries missed Our Oracle ERP system was critical in global management of supply chain Should not be supply constrained in H2 F12
Cochlear: H1 F12 Regional Split of Sales EMEA 1 41% CC growth 8% Americas 42% CC growth 1% 1 EMEA is Europe, Middle East and Africa 2 CC refers to constant currency Asia Pacific 17% CC growth 11%
Cochlear Americas: Sales in Constant Currency H1 F12 Americas sales of $149 million, up 1% in constant currency Clinic destocking due to implant supply constraint H2 Continued Hearing Health Seminars (market growth & awareness initiatives) On-line strategy roll out H1
Cochlear EMEA: Sales in Constant Currency H1 F12 EMEA sales of $143 million, up 8% in constant currency H2 Portfolio effect of products eg CI422 (Slim Straight Electrode) and geographies On-line strategy beginning to roll-out H1
Cochlear Asia Pac: Sales in Constant Currency H1 F12 Asia Pacific sales of $60 million, up 11% in constant currency H2 H1 Direct operations in India working well, including investment in infrastructure & people CI500 implant was not available in certain countries (eg Japan, China, so impact of recall less)
Cochlear Nucleus System Cochlear Implant Sound Processor Remote Assistant Programming Software. Custom Sound
Cochlear: Investing for long term growth Deepening global footprint /customer experience & service Technologic innovation (~13% of revenues) Significant investments in manufacturing and global supply chain Macquarie University hearing precinct as catalyst for global collaboration Investments in productivity/scalability including products (e.g. scalability suite driving simplification, automaticity, remote connectivity), transactions (online transactional tools) and customer interactions
Cochlear H1 F12 Overview Very challenging half year! However: Record revenue of $387.5 million Record new Nucleus implant recipients Recall costs fully expensed in H1 Global Cochlear team executed well on challenges, eg supply chain management The fundamentals of the business remain positive, no change to commitment to drivers of long term growth
For personal use only Cochlear Limited H1 F12 Financial Results Neville Mitchell, CFO
Cochlear H1 F12 Financial Performance H1 F12 $m H1 F11 $m % Change Total Revenue 387.5 377.1 3% EBIT * 108.7 121.1 10% Net Profit after Tax * 80.1 87.2 8% Product Recall Costs, net of tax 100.5 - Net (loss)/profit attributable to members (20.4) 87.2 123% Dividends Interim Dividend Record Date 28 February 2012 Payable Date 13 March 2012 120c 105c 14% Franking 60% 60% * These items exclude product recall expenses of $138.8 million before tax
Cochlear H1 F12 Product Recall Composition of Product Recall Expense H1 F12 $m Write down of Inventory 34.4 Impairment of Property, Plant and Equipment 14.0 Impairment of Intangibles 13.8 Warranty and other expenses 76.6 Cost of Sales Product recall before interest and tax 138.8 Income tax benefit (38.3) Total Product Recall Cost After Tax 100.5
Cochlear H1 F11 H1 F12 NPAT Reconciliation AUD Millions
Impact of Appreciating AUD on H1 F12 NPAT Income Statement Translation Impact A$m F/(U) Sales Revenue (17.9) Total Expenses including tax 8.0 (9.9) Transaction Impact - Increase from H1 F11 of FX gain on hedged sales 14.3 Translation Impact - Decrease over H1 F11 of FX gain on asset translation (3.2) Difference H1 F12 actual vs H1 F12 at H1 F11 rates Net difference actuals H1 F12 vs H1 F11 Net difference actuals H1 F12 vs H1 F11 Impact on H1 F12 NPAT of appreciating AUD 1.2
Cochlear H1 F12 Working Capital Inventory (Days Stock Held) / Debtors Days Outstanding H1 F12 Inventory days decreased to 168 (June F11 173 days) Debtor days 78 (June F11 74 days) Trade receivables at $148.3m (June F11 $165.9m)
Cochlear H1 F12 Cash / (Debt) Operations Loans and Borrowings 31 Dec 2011 $m 30 Jun 2011 $m Current (40.0) (60.0) Non-current (43.5) (3.0) Total Debt operations (83.5) (63.0) Cash 75.0 72.4 Net (Debt)/Cash operations (8.5) 9.4 Gearing ratio - operations (net debt/net debt + equity) 2% (2%) Total Loan Facilities 200.0 150.0 Unused Portion of Facility 107.2 79.5
Cochlear H1 F12 Overview Very challenging half year! However: Record revenue of $387.5 million Record new Nucleus implant recipients Recall costs fully expensed in H1 Excellent performance of global Cochlear team in facing the challenges, eg supply chain management The fundamentals of the business remain positive, no change to commitment to drivers of long term growth
Thank you Any questions?
FX Contract Cover and Rates as at 31 December 2011 Total FX cover at 31 Dec 2011 expressed in Foreign Currency USD 295.0m EUR 168.0m JPY 720m FX Hedges Expressed in AUD AUD 333.5m AUD 255.6m AUD 9.7m AUD Total 598.8m % of total cover (in AUD) 56% 43% 1% 100% 3 yr weighted average rates FX contracts at 31 Dec 11 0.88 0.66 74.2 FX contracts at 31 Dec 10 0.77 0.57 75.5 H2 F12 weighted average rates FX contracts at 31 Dec 11 Cover for H2 F12 (in AUD) 0.85 0.65 73.9 AUD 111.4m AUD 86.8m AUD 2.4m AUD 200.6m
Foreign Exchange Rates applied H1 F12 vs. H1 F11 H1 F12 H1 F11 % Change Average rates (used for translating P&L) USD 1.03 0.94 10% Euro 0.74 0.72 3% JPY 80.0 79.5 1% GBP 0.65 0.60 8% Contract rates (used to bring FX to Aust) USD 0.85 0.80 6% Euro 0.63 0.57 11% JPY 76.4 80.2 (5%)
Foreign Exchange Period end rates applied F12 vs. F11 31 Dec 2011 30 June 2011 % change Period end rates (used for translating Bal Sheet) USD 1.02 1.05 (3%) Euro 0.78 0.73 7% JPY 79.0 84.8 (7%)
Property, Plant & Equipment 31 Dec 2011 $m $m Gross value 30 June 2011 157.0 Accumulated depreciation (87.6) Net book value 69.4 F 12 movements Additions 9.6 Depreciation (8.2) Recall write-off (14.0) FX Impacts (0.4) Net book value December 2011 56.4
Corporate & Other Net Expenses H1 F12 $m H1 F11 $m FX Contracts (36.3) (21.9) Research and Development 57.4 50.9 Corporate Administration & Marketing 31.3 24.0 Corporate Other Income (0.7) (6.7) Corporate and other net expense (note 7) 51.7 46.3
Non-IFRS Financial Measures Non-IFRS financial measures Given the significance of the product recall and fx movements the directors believe the presentation of non-ifrs financial measures is useful for the users of this document as they reflect the underlying financial performance of the business. The non-ifrs financial measures included in this document have been calculated on the following basis: Excluding recall costs: IFRS measures adjusted for the costs of the product recall Constant currency: restatement of IFRS financial measures in comparative years using F12 FX rates Free cash flow: IFRS cash flow from operating and investing activities excluding interest and tax paid related to non-operating activities. The above non-ifrs financial measures have not been subject to review or audit. However, KPMG have separately undertaken a set of procedures to agree the non-ifrs financial measures disclosed to the books and records of the consolidated entity.